



Publikationsliste (Stand: 04/2023)

Dr. med. Peter Bojko,

Leitender Oberarzt Innere Medizin III – Hämatologie und Onkologie

Originalarbeiten

1. Weidmann B, Jansen W, **Bojko P**, Hänsele Th, Tauchert M, Niederle N (1993). Lebensbedrohliche Kardiotoxizität von 5-Fluorouracil. Intensivmed u Notfallmed 30:153-158
2. Weidmann B, Mülleneisen N, **Bojko P**, Niederle N (1994). Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer 73:2218-2222
3. Körbling M, Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, **Bojko P**, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin R (1996). Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant 18:885-890
4. Körbling M, Anderlini P, Durett A, Maadani F, **Bojko P**, Seong D, Khouri I, Andersson B, Mehra R, van Besien K, Mirza N, Przepiorka D, Champlin R (1996). Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34⁺ and CD34⁺Thy-1^{dim} CD38⁻ progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant 18:1073-1079
5. Hester J, **Bojko P**, Rondon G, Champlin R (1996). Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs. Transfus Sci 17:585-590
6. **Bojko P**, Hester JP, Durett AG, Maadani F, Körbling M, Champlin RE (1998). Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. J Clin Apheresis 13:7-15
7. **Bojko P**, Stellberg W, Küdde C, Scharifi M, Herrmann M, Mayer S, Harstrick A, Seeber S (1999). Kinetic study of CD34⁺ cells during peripheral blood stem cell collections. J Clin Apheresis 14:18-25
8. **Bojko P**, Nowak N, Moritz Th, Flasshove M, Harstrick A, Seeber S (1999). Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells. J Clin Apheresis 14:57-62
9. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhäuser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, **Bojko P**, Wolf HH, Schindler AE, Seeber S (2000). Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and

autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6:4209-4216

10. Bojko P, Scheulen ME, Hilger R, Oberhoff C, Schindler AE, Seeber S (2001). High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. J Cancer Res Clin Oncol 127:243-250

11. Kasimir-Bauer S, Mayer S, **Bojko P**, Borquez D, Neumann R, Seeber S (2001). Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res 7:1582-1589

12. Bojko P, Scharifi M, Stössel K, Seeber S (2002). Comparison of processing four and five times the patients' blood volume during peripheral blood stem cell collection and analysis of CD34+38- and CD34+49d+ subsets during apheresis. J Cancer Res Clin Oncol 128:19-28

13. Bojko P, Stellberg W, Mansmann V, Seeber S (2002). Analysis of commercial CD34 control samples for quality assurance. Clin Lab 48:117-124

14. Bojko P, Pawlowski D, Stellberg W, Schröder JK, Seeber S (2002). Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy. Ann Hematol 81:522-528

15. Bauer S, Hagen V, Pielken HJ, **Bojko P**, Seeber S, Schütte J (2001). Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 13:847-849

16. Bojko P, Hilger RA, Rühm SG, Dirsch O, Seeber S, Scheulen ME (2003). Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 31:487-491

17. Nowrousian MR, Waschke S, **Bojko P**, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S (2003). Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 14 (Suppl 1):i29-36

18. Bojko P, Akca A, Seeber S (2003). Outcome of 67 patients with solid tumors and relapse after high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant 31:995-1000

19. Bojko P, Welt A, Schleucher R, Borquez D, Scheulen ME, Vanhoefer U, Poettgen C, Stuschke M, Broelsch CE, Stamatis G, Wilke H, Seeber S, Harstrick A (2004). High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer.

Bone Marrow Transplant 34:637-643

20. Mueller S, Schuett P, **Bojko P**, Nowrousian MR, Hense J, Seeber S, Moritz T (2004). Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.

Ann Hematol 84:110-114

21. Hüttmann A, Schirsafi K, Seeber S, **Bojko P** (2004). Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

J Cancer Res Clin Oncol 131:152-156

22. Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoicznyk M, Flashove M, Hense J, **Bojko P**, Metz K, Moritz T, Seeber S, Nowrousian MR (2005). Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Eur J Haematol 74:40-46

23. Abenhardt W, Bosse D, Böning L, **Bojko P**, Hitz H, Völkl S, Fromm M, Mittermüller J, Gödel N, Schick HD, Dietzfelbinger H, Hinke A (2006). Antiemetische Therapie mit 5-HT3-Antagonisten in der onkologischen Praxis.

Dtsch Med Wochenschr 131:2707-2712

24. Schnittger S, Bacher U, Haferlach C, Beelen D, **Bojko P**, Bürkle D, Dengler R, Distelrath A, Eckart M, Ecker R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T (2009). Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.

Haematologica 94:141-144

25. Bojko P, Abenhardt W, Schnittger S, Haferlach T (2009). Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.

Onkologie 32:191-195

26. Bojko P, Schimmel G, Bosse D, Abenhardt W (2012). Oral cyclophosphamide in patients with advanced solid tumors.

Onkologie 35:35-38

27. Fischer I, Besseler M, **Bojko P**, Heim ME, Koller M, Milani V, Riedner C, Rinas N, Ruffer JU, Schneider E, Heußner P, Schlimok G (2016). Zwei Jahre Tumor-Fatigue-Sprechstunde der Bayerischen Krebsgesellschaft e.V.

Forum 3:247-251

28. Fischer I, Riedner C, **Bojko P**, Heim ME, Ruffer JU, Besseler M, Heußner P, Milani V, Rinas N, Schlimok G, Schneider E, Koller M (2016). Consultation program for patients with cancer-related fatigue; a systematic evaluation of the experiences of the Bavarian Cancer Society.

Oncol Res Treat 39:646-651

29. Fischer I, Heim ME, Besseler M, **Bojko P**, Milani V, Riedner C, Rinas N, Schneider E, Koller M, Schlimok G, Heußner P, Ruffer JU (2017). Tumor-Fatigue-Sprechstunde der Bayerischen Krebsgesellschaft e.V. Was passiert da eigentlich? Teil I (Differential-) Diagnostik

Forum

30. Fischer I, Heim ME, Besseler M, **Bojko P**, Milani V, Riedner C, Rinas N, Schneider E, Koller M, Schlimok G, Heußner P, Ruffer JU (2017). Tumor-Fatigue-Sprechstunde der Bayerischen Krebsgesellschaft e.V. Was passiert da eigentlich? Teil II Beratung

Forum

31. Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P (2017). Nivolumab in HIV-related non-small-cell lung cancer.

Ann Oncol 28: 2890

32. Stemler J, Bruns C, Mellinshoff SC, Alakel N, Akan H, Ananda-Rajah M, Auberger J, **Bojko P**, Chandrasekar PH, Chayakulkeeree M, Cozzi JA, de Kort EA, Groll AH, Heath CH, Henze L, Jimenez MH, Kanj SS, Khanna N, Koldehoff M, Lee DG, Mager A, Marchesi F, Martino-Bufarull R, Nucci M, Oksi J, Pagano L, Phillips B, Prattes J, Pyrasopoulou A, Rabitsch W, Schalk E, Schmidt-Hieber M, Sidharthan N, Soler-Palacin P, Stern A, Weinbergerova B, El Zakhem A, Cornely OA, Koehler P (2020). Baseline chest computed tomography as standard of care in high-risk hematology patients.

Journal of Fungi 6:1-13

33. Höllein A, **Bojko P**, Schulz S, Neitz J, Stötzer O, Pihusch R, Abedinpour F, Schmidt B, Hentrich M (2021). Characteristics and outcome of patients with cancer and COVID-19: results from a cohort study.

Acta Oncologica 60:24-27

34. Rackl E, Li L, Klauer LK, Ugur S, Pepeldjiyska E, Seidel CL, Gunsilius C, Weinmann M, Doraneh-Gard F, Reiter N, Plett C, Amberger DC, Bojko P, Kraemer D, Schmohl J, Rank A, Schmid C,

Schmetzer HM (2022). Dendritic cell-triggered immune activation goes along with provision of (leukemia-specific) integrin beta 7-expressing immune cells and improved antileukemic processes. Int J Mol Sci 24:463

35. Wimmer T, Mattes R, Stemmler HJ, Hauck F, Schulze-Koops H, Stecher SS, Starck M, Wendtner CM, Bojko P, Hentrich M, Nickel KE, Götze KS, Bassermann F, von Bergwelt-Baildon M, Spiekermann K (2023). sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study. Blood Adv 14:832-844

Übersichtsarbeiten

1. **Bojko P** (2006). Individualisierte Supportivtherapie mit G-CSF oder Antibiotika. Onkologisch 2/2006:4-5

2. Fischer I, Weis J, Ruffer JU, Heim ME, **Bojko P**, Ostgathe C (2017). Tumorassoziierte Fatigue in der Palliativsituation – Grundlagen, Diagnostik und evidenzbasierte Therapie. Z Palliativmedizin 18:97-110

3. Fischer I, Weis J, Ruffer JU, Heim ME, **Bojko P**, Ostgathe C (2017). Tumorassoziierte Fatigue in der Palliativsituation. Frauenheilkunde up2date 11:83-96

Buchbeiträge

Bojko P (2003). Stammzellgestützte Hochdosistherapie bei soliden Tumoren. In: Seeber S, Schütte J (Hrsg.) - Therapiekonzepte Onkologie. 4. Auflage, Springer-Verlag, Berlin, Heidelberg, New York [usw.]

Flasshove M, **Bojko P** und Moritz T (2007). Hochdosistherapie - Stammzellgestützte Hochdosistherapie bei soliden Tumoren. In: Seeber S, Schütte J (Hrsg.) - Therapiekonzepte Onkologie. 5. Auflage, Springer-Verlag, Berlin, Heidelberg, New York [usw.]

Abenhardt W, Artmann A, Astner S, Bastert G, **Bojko P**, de Waal JC, Eiermann W, Engel J, Heinemann V, Janni W, Kessler M, Lutz L, Rauthe G, Sommer H, Stieber P, Wolf M (2007). Manual Mammakarzinome. Empfehlungen zur Diagnostik, Therapie und Nachsorge – Nachsorge. Tumorzentrum München. 11. Auflage, W. Zuckschwerdt Verlag München.

Das MSD Manual. 7. Auflage, Urban & Fischer (2007). Übersetzung für die deutsche Ausgabe (Störungen der Eosinophilen, Lymphome, Plasmazellkrankheiten)

Zöllner A, Schiel X, Dechow T, **Bojko P**, Hiller E, Dietzfelbinger H, Dreyling M (2012). Manual Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge – Nachsorge. Tumorzentrum München. 9. Auflage, W. Zuckschwerdt Verlag München.

Olipitz W, **Bojko P**, Spiekermann K, Verbeek M, Schmid C, Tischer J, Jost P (2015). Manual Leukämien, myelodysplastische Syndrome und myeloproliferative Neoplasien. Tumorzentrum München. 4. Auflage, W. Zuckschwerdt Verlag München.

Hentrich M, Rassmann I, Graf N, **Bojko P**, Straka C (2017). Manual Multiples Myelom. Tumorzentrum München. 5. Auflage, W. Zuckschwerdt Verlag München

Publizierte Abstracts

1. Weidmann B, Jansen W, **Bojko P**, Rappert B, Niederle N (1993). Life-threatening myocardial impairment induced by 5-fluorouracil (5-FU). Eur J Cancer 29A (Suppl 6):S111

2. Weidmann B, Mülleneisen N, **Bojko P**, Heider A, Tauchert M, Niederle N (1993). Hypersensitivity reactions to carboplatin. Eur J Cancer 29A (Suppl 6):S208

3. Weidmann B, Jansen W, **Bojko P**, Hänsele T, Hinzmann S, Tauchert M (1994). Sumatriptan-induzierter Myokardinfarkt. Intensivmed u Notfallmed 31:353

4. **Bojko P**, Hester JP, Durett AG, Körbling M, Champlin RE (1995). Identification of megakaryocyte precursors in peripheral blood stem cell collections of normal donors. Blood 86 (Suppl 1):107a

5. **Bojko P**, Durett AG, Hester JP, Körbling M (1995). Magnetic cell sorting to purify G-CSF mobilized and apheresis collected CD34+ progenitor cells for transplantation. Blood 86 (Suppl 1):229a

6. **Bojko P**, Kloster G, Weidmann B, Gaczkowski A, Halbe J, Niederle N (1995). Double high-dose chemotherapy with peripheral blood stem cell transplantation in patients with metastatic breast cancer and high grade lymphoma. Blood 86 (Suppl 1):938a

7. Körbling M, Anderlini P, Durett AG, Maadani, F, Mirza N, **Bojko P**, Miller P, Sundberg J, Seong D, Deisseroth A, Przepiorka D, Champlin R (1995). Allogeneic blood stem cell transplantation: delayed effects of rhG-CSF treatment and stem cell apheresis on kinetics of CD34+ cells, subsets (CD34+Thy-1dimCD38-) and lymphoid subsets in 10 normal donors. Blood 86 (Suppl 1):406a

8. **Bojko P**, Käding J, Köster W, Mayer S, Harstrick A, Seeber S (1996). Stem cell apheresis data from 320 separations on 187 patients with solid tumors and lymphomas. Blood 88 (Suppl 1):233b

9. **Bojko P**, Stellberg W, Küdde C, Scharifi M, Herrmann M, Mayer S, Harstrick A, Seeber S (1997). Kinetic study of CD34+ cells during large volume peripheral blood stem cell collections. Blood 90 (Suppl 1):210a
10. **Bojko P**, Nowak N, Moritz T, Flasshove M, Harstrick, A, Seeber S (1998). Thrombopoietin serum levels at the start of mobilization, collection, and retransfusion of autologous peripheral blood stem cells. Blood 92 (Suppl 1):297b
11. Kasimir-Bauer S, Klaassen U, Borquez D, **Bojko P**, Seeber S (1999). Frequency and characterization of isolated carcinoma cells in bone marrow and stem cell grafts of patients with advanced breast cancer: A monitoring study. Proc Am Assoc Cancer Res 40:496
12. Harstrick A, Schleucher N, Andresen E, Kolkenbrock S, Schröder J, Welt A, Schütte J, Kloke O, Nowrousian MR, **Bojko P**, Klaassen U, Seeber S (1999). Tandem high-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by peripheral blood stem cell retransfusion in cisplatin refractory germ cell cancer patients. Proc Am Soc Clin Oncol 18:327a
13. **Bojko P**, Daneshvaran J, Hapke G, Trarbach T, Schröder J, Harstrick A, Seeber S (1999). Comparison of early vs. late antibiotic prophylaxis in patients receiving high-dose chemotherapy with peripheral blood stem cell transplantation. Blood 94 (Suppl 1):365b
14. Borquez D, Vanhoefer U, Oberhoff C, Hense J, Mayer S, **Bojko P**, Harstrick A, Seeber S (2000). Phase I/II study of vinorelbine in combination with a weekly schedule of folinic acid and infusional 5-FU in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 19:109a
15. **Bojko P**, Daneshvaran J, Trarbach T, Mansmann V, Schröder J, Seeber S (2000). Antibiotic prophylaxis after high-dose chemotherapy and peripheral blood stem cell transplantation. Onkologie 23 (Sonderheft 7):128
16. Pawlowski D, **Bojko P**, Schröder J, Stellberg W, Seeber S (2000). CD34+ subgroups and thrombopoietin and flt-3 ligand serum levels in patients receiving high-dose chemotherapy and peripheral blood stem cell transfusion: impact on engraftment. Ann Oncol 11 (Suppl 4):16
17. **Bojko P**, Hilger R, Scheulen ME, Oberhoff C, Schindler AE, Seeber S (2000). High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. Ann Oncol 11 (Suppl 4):82
18. **Bojko P**, Stellberg W, Mansmann V, Seeber S (2000). CD34+ reference samples for quality assurance in high-dose chemotherapy. Blood 96 (11), 314b

19. **Bojko P**, Pawlowski D, Stellberg W, Schröder JK, Seeber S (2001). Flt3-ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization and high-dose chemotherapy. *Blood* 98 (11):329b
20. **Bojko P**, Waschek S, Seeber S, Nowrousian MR (2001). Comparison of G-CSF and GM-CSF in combination with chemotherapy for peripheral blood stem cell mobilization. *Blood* 98 (11):177a
21. Nowrousian MR, Ernst S, Beling C, Fink H, Welt A, Schütte J, Moritz T, Flasshove M, **Bojko P**, Seeber S, Metz KA, Stuschke M (2001). CEBOPP/VIML followed by radiotherapy for unfavorable early-stage or advanced-stage Hodgkin's disease. *Blood* 98 (11):131a
22. Hilger RA, Richly H, Grubert M, Strumberg D, Oberhoff C, **Bojko P**, Scheulen ME, Seeber S (2001). Pharmacokinetics of encapsulated as well as free doxorubicin and its metabolites after intravenous infusion of caelyx. *Proc Am Soc Clin Oncol* 20:116a
23. **Bojko P**, Seeber S (2001). Marginal benefit of large-volume peripheral blood stem cell collection: comparison of processing four and five times the patients' blood volume and analysis of CD34+38- and CD34+49d+ subsets during apheresis. *Onkologie* 24 (Sonderheft 6):157-158
24. Bauer S, Hartung J, Gauler T, Gocke P, Flasshove M, Nowrousian M, **Bojko P**, Hense J, Seeber S, Schuette J (2002). Analysis of gemcitabine activity in advanced soft tissue sarcoma. *Proc Am Soc Clin Oncol* 21:408a
25. Schleucher N, Tewes M, Achterrath W, **Bojko P**, Eberhardt W, Wilke H, Seeber S, Vanhoefer U (2002). Phase I study of a weekly schedule of infusional high-dose 5-fluorouracil/leucovorin/irinotecan in combination with biweekly cisplatin as first-line chemotherapy for metastatic gastric carcinoma. *Proc Am Soc Clin Oncol* 21:111b
26. **Bojko P**, Akca A, Seeber S (2002). Outcome of 67 patients with solid tumors and relapse after high-dose chemotherapy and peripheral blood stem cell transplantation. *Blood* 100 (11):469b
27. **Bojko P**, Neumann C, Steiniger H, Gauler T, Seeber S (2003). **Short-term incubation of autologous peripheral blood stem cells (PBSC) with glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF).**
Blood 102 (11):425b
28. Elmaagacli AH, Peceny R, Steckel NK, Trensche R, Koldehoff M, **Bojko P**, Ottinger H, Beelen DW (2003). Outcome of transplantation of highly purified peripheral blood CD34+ cells with T cell add-back compared to unmanipulated bone marrow or peripheral blood stem cells

from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukaemia.

Blood 102 (11):910a

29. Peceny R, Ott R, Volk O, Planker M, **Bojko P**, Elmaagacli AH, Beelen DW (2003). **Isolated myocardial relapse of chronic myelogenous leukemia in lymphoid blast crisis after allogeneic stem cell transplantation.**

Blood 102 (11):460b

30. Schnittger S, Haferlach C, Beelen DW, Bojko P, Dengler R, Diestelrath A, Eckart MJ, Eckert R, Fries S, Köchling G, Laubenstein HP, Planker M, Pihusch R, Kern W, Haferlach T (2007). **Detection of three different MPLW515 mutations in 10.1% of all JAK2 V617F unmutated ET and 9.3% of all JAK2 V617F unmutated OMF: a study of 387 patients.**

Blood 110 (11):750a

31. **Bojko P**, Abenhardt W, Schnittger S, Haferlach T (2007). Analysis of the V617F mutation of the JAK2- and the W515 mutation of the MPL gene in patients with chronic myeloproliferative disease (CMPD) treated in an outpatient practice.

Blood 110 (11): 231b

32. Stemler J, Bruns C, Mellinghoff SC, Alakel N, Akan H, Ananda-Rajah M, Auburger J, **Bojko P**, Chandrasekar H, Chayakulkeeree M, Cozzi JA, de Kort EA, Groll AH, Heath CH, Henze L, Jimenez MH, Kanj SS, Khanna N, Koldehoff M, Lee DG, Mager A, Marchesi F, Martino-Bufarull R, Nucci M, Oksi J, Pagano L, Phillips B, Prattes J, Pyrpasopoulou A, Rabitsch W, Schalk E, Schmidt-Hieber M, Sidharthan N, Soler-Palacin P, Stern A, Weinbergerova B, El Zakhem A, Cornely OA and Koehler P (2020). Baseline chest computed tomography as standard of care in high-risk hematology patients.

Journal of Fungi 6 (36)

NICHT PUBLIZIERTE VORTRÄGE

a) Eingeladene wissenschaftliche Vorträge

1. Einladung zum XIII. Congress of the European Society for Haemapheresis in Riva del Garda, Italien, vom 16. - 19. September 2001.
Vortragsthema: Marginal benefit of large-volume peripheral blood stem cell collection: comparison of processing four and five times the patients' blood volume and analysis of CD34+38- and CD34+49d+ subsets during apheresis.
2. Einladung zum 10th Annual International Symposium on Recent Advances in Stem Cell Transplantation, Satelliten-Workshop in Heidelberg am 24.04.2002.
Vortragsthema: Analyse kommerzieller CD34-Reagenzien für die Qualitätskontrolle.

b) Fortbildungsvorträge

1. Einladung zum Onkologischen Mittagsseminar in der Inneren Klinik und Poliklinik (Tumorforschung) des Universitätsklinikums Essen am 10.04.1999.
Vortragsthema: Thrombopoetin - Präklinik und Klinik.
2. Einladung zum Onkologischen Mittagsseminar in der Inneren Klinik und Poliklinik (Tumorforschung) des Universitätsklinikums Essen am 21.02.2000.
Vortragsthema: Hochdosistherapie - Studienkonzepte.
3. Einladung zur Fortbildung in der Praxisgemeinschaft Paur und Kohnke in Remscheid am 07.06.2000.
Vortragsthema: Aktuelle Therapiestandards bei kolorektalen Tumoren: Aktuelle Entwicklungen in der onkologischen Therapie.
4. Einladung zur Fortbildungsveranstaltung der Inneren Klinik und Poliklinik (Tumorforschung) des Universitätsklinikums Essen am 20.01.2001 zum Einsatz von hämatopoetischen Wachstumsfaktoren in der Onkologie unter besonderer Berücksichtigung der Hochdosis-Chemotherapie.
Vortragsthema: Engraftment nach Hochdosis-Chemotherapie und autologer peripherer Blutstammzelltransplantation.
5. Einladung zum Frühjahrssymposium des Westdeutschen Tumorzentrum Essen e.V. im Universitätsklinikum Essen am 26.05.2001.
Vortragsthema: Rolle der Hochdosistherapie für die Behandlung solider Tumoren.
6. Einladung zum Onkologie-Symposium in die Deister Weser Klinik in Bad Münder am 23.11.2002.
Vortragsthema: Adjuvante und palliative Chemotherapie des Magenkarzinoms: Aktuelle Therapiestandards beim Magenkarzinom.
7. Faszination Interdisziplinäre Onkologie: Veranstaltungsreihe des Interdisziplinären Tumor-Therapie-Zentrums. Das Tumorrezidiv des Prostatakarzinoms – eine interdisziplinäre Herausforderung. Klinikum rechts der Isar, München; 14.07.2004.
Vortragsthema: Zytotoxische Chemotherapie des Prostatakarzinoms – ein Überblick.

8. Neues zur Therapie des Mammakarzinoms. Krankenhaus München-Schwabing, Abteilung für Gynäkologie und Geburtshilfe; 17.02.2005.
Vortragsthema: Chemotherapiebedingte Nebenwirkungen aus hämato-onkologischer Sicht.
9. Post ASCO – Workshop, AstraZeneca. Hotel Le Meridien, München; 02.06.2005.
Vortragsthema: Mammakarzinom.
10. 2. Priener Onkologie Symposium; 10.02.2007.
Vortragsthema: Internistisch-onkologische Therapie beim Kolon- und Rektumkarzinom; 10.02.2007
11. Hämatologisches Symposium: Schwerpunkt: Myeloproliferative Neoplasien.
Vortragsthema: MPN und Verdacht auf MPN: Erfahrungen aus einer Praxis; 24.10.2009
12. Onkologisches Halbjahressymposium des Tumorzentrums München Süd im Klinikum Harlaching: Urologische Tumoren – eine interdisziplinäre Herausforderung.
Vortragsthema: Palliative Therapie des Nierenzellkarzinoms: Wer die Wahl hat, hat die Qual; 16.11.2011
13. Update – Therapiemanagement und Abrechnung in der Hämatologie/Onkologie .
Vortragsthema: Der ältere Patient mit Multiplem Myelom: Therapiestrategien im Wandel; 04.05.2015